Product Description
Mechanisms of Action: TMEM16A Activator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Indonesia | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: AOP Orphan AG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Cystic Fibrosis
Phase 1: Oncology Unspecified|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PicTURE | P1 |
Completed |
Healthy Volunteers|Oncology Unspecified |
2021-12-14 |
|
| 2005-005594-29 | P3 |
Terminated |
Cystic Fibrosis |
2021-04-23 |
|
| 2006-006693-24 | P3 |
Completed |
Cystic Fibrosis |
2009-07-15 |
|
| Moli1901-010B | P2 |
Completed |
Cystic Fibrosis |
2009-07-01 |